30 results
8-K
EX-99.1
COGT
Cogent Biosciences Inc
6 Jul 20
Unum Therapeutics Inc. Announces Acquisition of Kiq LLC
10:31am
to drive forward our mission of developing novel, best-in-class therapeutics for patients with the greatest need, and we thank our Board members, past … discovery expertise,” said Peter Harwin, Managing Member, Fairmount Funds. “We look forward to working with Unum to continue its mission
POS AM
COGT
Cogent Biosciences Inc
6 May 22
Prospectus update (post-effective amendment)
4:33pm
Gibson, Dunn & Crutcher LLP
555 Mission Street
San Francisco, CA 94105
(415) 393-8373
Approximate date of commencement of proposed sale
8-K
EX-99.1
COGT
Cogent Biosciences Inc
5 Oct 20
Unum Therapeutics Announces Company Name Change to Cogent Biosciences, Highlights Recent Scientific and Operational Progress
9:08am
under a new CUSIP number, 19240Q102. The new name reflects Cogent’s mission to design rational precision therapies that treat the underlying cause
8-K
EX-99.1
COGT
Cogent Biosciences Inc
8 Aug 23
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2023 Financial Results
8:14am
financial results for the second quarter ended June 30, 2023.
“Cogent continues to deliver on our mission to bring best-in-class therapies to patients
8-K
EX-99.1
COGT
Cogent Biosciences Inc
9 Nov 20
Cogent Biosciences Reports Third Quarter 2020
7:33am
mission to design rational precision therapies that treat the underlying cause of disease in order to improve patients’ lives.
Out licensed BOXR
8-K
EX-99.1
v6ndzepgfdhtqzs1ge
2 Nov 23
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2023 Financial Results
9:18am
8-K
EX-1.1
7ox36teojfp
2 Dec 20
Entry into a Material Definitive Agreement
5:08pm
8-K
EX-1.1
xwdt762gxyj13omyr29z
15 Jun 22
Entry into a Material Definitive Agreement
5:18pm
8-K
EX-1.1
cac4ew37icyhs
8 Jun 23
Entry into a Material Definitive Agreement
4:31pm
8-K/A
EX-1.1
zctmh35
16 Jun 22
Entry into a Material Definitive Agreement
5:03pm